Xcopri
Phase 3Small molecule
Xcopri is one of 20 small molecule programs targeting Partial Epilepsy. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Partial Epilepsy
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Trileptal
NovartisApproved
Vimpat
UCBApproved
Depakote
AbbVieApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Fycompa
CCatalyst Biosciences
Approved
Neurontin
VViatris Specialty LLC
Approved
Fintepla
IImmedica Pharma AB
Approved
Benemid
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xcopri. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSK Life Science, Inc.